Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
It is shown, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations. Expand
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. Expand
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines
- E. Thompson, S. Paik, +9 authors R. Dickson
- Biology, Medicine
- Journal of cellular physiology
- 1 March 1992
Data from these cell lines suggest that human breast cancer progression results first in the loss of ER, and subsequently in VIM acquisition, the latter being associated with increased metastatic potential through enhanced invasiveness. Expand
Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.
- L. Engel, N. Young, T. S. Tralka, M. Lippman, S. O'Brien, M. Joyce
- Medicine, Biology
- Cancer research
- 1 October 1978
Three continuous lines of mammary tumor cells have been established from malignant effusions of two women with breast cancer, and two of the cultures, although derived from the same patient, have stable differences in their karyotypes. Expand
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
It is concluded that raloxifene continues to reduce the risk of breast cancer in women with osteoporosis after 4 years of treatment, through prevention of new cancers or suppression of subclinical tumors, or both. Expand
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays.
- J. Rae, M. Johnson, M. Lippman, D. Flockhart
- Biology, Medicine
- The Journal of pharmacology and experimental…
- 1 December 2001
Analysis of expression microarrays makes it clear that rifampin treatment brings about broad changes in the pattern of gene expression, rather than increased expression of a small number of metabolic enzymes. Expand
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.
- J. Jacobson, D. Danforth, +7 authors P. Okunieff
- The New England journal of medicine
- 6 April 1995
In the management of stage I and II breast cancer, breast conservation with lumpectomy and radiation offers results at 10 years that are equivalent to those with mastectomy. Expand
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.
- Y. Zhai, R. Guo, +20 authors D. Yang
- Medicine, Biology
- The Journal of clinical investigation
- 15 September 1998
The data suggest that LIGHT triggers distinct biological responses based on the expression patterns of its receptors on the target cells and may play a role in the immune modulation and have a potential value in cancer therapy. Expand
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
The data suggest that some breast cancer patients who acquire resistance to tamoxifen may not develop cross-resistance to treatment with steroidal antiestrogens. Expand